Communiqués Keymed Biosciences Inc.

Actions

Marché Fermé - Hong Kong S.E. Autres places de cotation 10:08:05 10/08/2026			Varia. 5j.	Varia. 1 janv.
81,90 ^HKD	+0,06%		+10,23%	+53,23%

05:27	L'essai clinique de Keymed Biosciences sur un traitement des polypes nasaux atteint tous ses objectifs de phase 2	MT
28/07	Keymed Biosciences Inc. obtient des résultats préliminaires positifs dans l'essai clinique mondial de phase III Clarity-Gastric01 pour le CMG901 (AZD0901)	CI

16/06/25	Keymed Biosciences Announces The Latest Clinical Trial Results Of Cm336 Published In The New England Journal Of Medicine	AQ
10/02/25	Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis	AQ
10/01/25	Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs	PR
24/12/24	Keymed Biosciences Announces Approval Of Stapokibart For The Treatment Of Chronic Rhinosinusitis With Nasal Polyposis	AQ
30/03/23	License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed	AQ
18/03/23	Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration	PR
23/02/23	AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate	AQ
07/03/22	Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect	PR
18/02/22	Keymed Bio Joins Hang Seng Family of Indexes	PR